ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.640
+0.050 (3.14%)
At close: Apr 28, 2026, 4:00 PM EDT
1.700
+0.060 (3.66%)
After-hours: Apr 28, 2026, 5:32 PM EDT
ALX Oncology Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ALX Oncology Holdings stock have an average target of 3.50, with a low estimate of 1.00 and a high estimate of 5.00. The average target predicts an increase of 113.41% from the current stock price of 1.64.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for ALX Oncology Holdings stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $5 | Buy | Initiates | $5 | +204.88% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +143.90% | Mar 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $3 → $4 | Buy | Maintains | $3 → $4 | +143.90% | Feb 5, 2026 |
| UBS | UBS | Strong Buy Maintains $1.2 → $1 | Strong Buy | Maintains | $1.2 → $1 | -39.02% | May 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | +21.95% | May 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.78
from -1.90
EPS Next Year
-0.71
from -0.78
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.68 | -0.57 | |||
| Avg | -0.78 | -0.71 | |||
| Low | -0.97 | -0.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.